Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18243 patients

Background Neoadjuvant therapy has theoretical benefits for pancreatic cancer; however, its association with perioperative outcomes remains controversial. This study sought to evaluate variation in use of neoadjuvant therapy and outcomes following pancreatic resection. Methods The National Cancer Da...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2017-08, Vol.116 (2), p.127
Main Authors: Youngwirth, Linda M, Nussbaum, Daniel P, Thomas, Samantha, Adam, Mohamed A, Blazer, Dan G, Roman, Sanziana A, Sosa, Julie A
Format: Article
Language:English
Subjects:
Biopsy
Cancer surgery
Cancer therapies
Pancreatic cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Neoadjuvant therapy has theoretical benefits for pancreatic cancer; however, its association with perioperative outcomes remains controversial. This study sought to evaluate variation in use of neoadjuvant therapy and outcomes following pancreatic resection. Methods The National Cancer Data Base (1998-2011) was queried for patients with Stage I or II pancreatic adenocarcinoma who underwent pancreaticoduodenectomy. Subjects were classified by use of neoadjuvant chemotherapy and/or radiation therapy. Factors associated with use of neoadjuvant therapy were evaluated, and outcomes were compared. Results A 18243 patients were identified; 1375 (7.5%) received neoadjuvant therapy. From 1998 to 2011, use of neoadjuvant therapy increased from 4.3% to 17.0%. Patients receiving neoadjuvant therapy were younger (63.1 vs 66.1 years, P=0.001) and more likely to receive treatment at an academic facility (64.4% vs 51.4%, P
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.24630